BACKGROUND: The objective of this study was to determine whether health care disparities exist in management of Graves' disease. METHODS: Patients treated for Graves' disease from 1999 to 2009 were divided into medical and surgical treatment groups. A comparative analysis of age, sex, race, health insurance, and income was completed. Address and/or zip code were geocoded and median income was determined from census data. RESULTS: A total of 634 patients were treated for Graves' disease; 535 (84%) medically and 99 (16%) surgically. Mean age (40 ± 15 vs 43 ± 11 y), percentage of women (84% vs 91%), and racial distribution were similar in the 2 groups (P > .05). In the surgical group, median income was lower ($31,530 vs $34,404; P = .07) and 52% of patients were uninsured compared with 30% of patients treated medically (P < .0001). CONCLUSIONS: A disproportionate number of uninsured patients underwent thyroidectomy for Graves' disease. Social and economic factors may have a role in determining definitive therapy for Graves' disease.
BACKGROUND: The objective of this study was to determine whether health care disparities exist in management of Graves' disease. METHODS:Patients treated for Graves' disease from 1999 to 2009 were divided into medical and surgical treatment groups. A comparative analysis of age, sex, race, health insurance, and income was completed. Address and/or zip code were geocoded and median income was determined from census data. RESULTS: A total of 634 patients were treated for Graves' disease; 535 (84%) medically and 99 (16%) surgically. Mean age (40 ± 15 vs 43 ± 11 y), percentage of women (84% vs 91%), and racial distribution were similar in the 2 groups (P > .05). In the surgical group, median income was lower ($31,530 vs $34,404; P = .07) and 52% of patients were uninsured compared with 30% of patients treated medically (P < .0001). CONCLUSIONS: A disproportionate number of uninsured patients underwent thyroidectomy for Graves' disease. Social and economic factors may have a role in determining definitive therapy for Graves' disease.
Authors: Geeta Lal; Philip Ituarte; Electron Kebebew; Allan Siperstein; Quan-Yang Duh; Orlo H Clark Journal: Thyroid Date: 2005-06 Impact factor: 6.568
Authors: Michael S Barakate; Gaurav Agarwal; Tom S Reeve; Bruce Barraclough; Bruce Robinson; Leigh W Delbridge Journal: ANZ J Surg Date: 2002-05 Impact factor: 1.872
Authors: Haejin In; Elizabeth N Pearce; Arthur K Wong; James F Burgess; David B McAneny; Jennifer E Rosen Journal: J Am Coll Surg Date: 2009-05-28 Impact factor: 6.113
Authors: Vincent T Wu; Allison W Lorenzen; Anna C Beck; Vincent J Reid; Sonia L Sugg; James R Howe; Janet H Pollard; Geeta Lal; Ronald J Weigel Journal: Surgery Date: 2016-11-15 Impact factor: 3.982
Authors: Dawn M Elfenbein; David F Schneider; Jeffrey Havlena; Herbert Chen; Rebecca S Sippel Journal: Ann Surg Oncol Date: 2014-09-23 Impact factor: 5.344